SyntheticMR’s Innovative SyMRI Software Receives Regulatory Approval in Singapore

SyntheticMR announced today that their quantitative imaging software solution SyMRI 12.1 has received regulatory approval in Singapore and can be sold and distributed in this market. 

“We are thrilled to receive regulatory approval in Singapore, we look forward to starting providing this market with our unique software SyMRI,” says Ulrik Harrysson, CEO at SyntheticMR. “We keep working on our goal to establish SyMRI as a standard of care globally and to support customers and clinicians from all over the world in their daily workflows. This regulatory approval in Singapore is a vital step on that journey.” 

SyMRI provides multiple contrast-weighted images and quantitative information about the patient in a single fast scan, enabling users to speed up their imaging workflow and add objective decision support to their practice. 

Learn more about SyMRI and what this exciting expansion has to offer! 

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI^®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.